Dr. Andrew Michael Schimel, MD

Dr. Schimel practices at Miami Plastic Surgery in Miami, Florida.

Dr. Schimel's NPI, 1174714836, was assigned on August 7, 2007. Dr. Schimel graduated from Feinberg School of Medicine in 2006. Dr. Schimel holds Florida license ME106542.

Dr. Schimel's primary practice is Miami Plastic Surgery, at 8940 N Kendall Dr, Miami, FL 33176 in Miami-Dade County. The practice phone is (305) 595-2969.

Dr. Schimel's primary practice is Miami Plastic Surgery in Miami, Florida. Dmand AI also links Dr. Schimel to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schimel practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Schimel's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Schimel is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Schimel's licenses on file in 3 states: Florida, Missouri and Illinois.

Dmand AI lists age-related macular degeneration, cataract, dry eye, eye infection or inflammation, eyelid inflammation, glaucoma, hypertensive retinopathy and laser destruction of retinal or choroid lesions among the conditions Dr. Schimel treats.

CMS data shows 18,020 Medicare services from Dr. Schimel across 14 procedure codes in 2024, for 965 Medicare patients. Medicare paid $2,090,681 for them.

CMS counts 965 Medicare patients who saw Dr. Schimel in 2024. The largest group is 75 to 84, with 411 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.28, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Schimel's median patient age at 75, with 58% women.

In 2024, Dr. Schimel wrote 602 Medicare Part D claims for 239 patients. 42% of them were for generic drugs. CMS names the drug for 499 of them, across 7 drugs with 11 or more claims each, at $234,515 in total drug cost. In 2023, CMS named 538 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Schimel for performance year 2024, reported as part of a group. Dr. Schimel accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 15 papers to Dr. Schimel, published from 2011 to 2021. 2011 was the busiest year, with 2. The most frequent topics are Endophthalmitis, Anti-Bacterial Agents and Intravitreal Injections. Dr. Schimel has published most often in Arch Ophthalmol. Dr. Schimel's most frequent co-authors are Harry W. Flynn, MD, Eduardo Alfonso, MD and Michael H. Shannon, MD.

CMS Open Payments shows 810 general payments to Dr. Schimel from 42 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 74% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $392,555.

Dmand AI lists 1 award for Dr. Schimel, most recently CMS Stage 1 EHR in 2013.

Dr. Schimel graduated from Feinberg School of Medicine in 2006.

Dr. Schimel is in network with 10 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.